p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients

Pharmacogenetics and Genomics

Volumn 16, Issue 5, 2006, Pages 347-351

  Wegman, Pia ^a   Stål, Olle ^a   Askmalm, Marie Stenmark ^a   Nordenskjöld, Bo ^a   Rutqvist, Lars Erik ^b   Wingren, Sten ^a  

^a Division of Social Medicine and Public Health Science   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; p53 codon 72; Polymorphism; Tamoxifen therapy

Indexed keywords

ARGININE; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROLINE; PROTEIN P53; TAMOXIFEN;

AGED; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CODON; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 33645921956     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000204997.84182.69     Document Type: Article

References (24)

1. Early Breast Cancer Trialist's Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 352:1451-1467.
2. Walker K, Levine A. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A 1996; 93:15335-15340.
3. Sakamuro D, Sabbatini P, White E, Prendergast G. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogens 1997; 15:887-898.
4. Dumont P, Leu I, Ju J, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33:357-365.
5. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004; 108:196-199.
6. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004; 23:3328-3337.
7. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000; 25:47-54.
8. Brooks LA, Tidy JA, Gusterson B, Hiller L, O'Nions J, Gasco M. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res 2000; 60:6875-6877.
9. Tada M, Furuuchi K, Kaneda M, Matsumoto J, Takahashi M, Hirari A, et al. Inactive the remaining p53 allele or the alternate p73? Preferential selection of the arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis 2001; 22:515-517.
10. Furihata M, Takeuchi T, Matsumoto M, Kurabayashi A, Ohtsuki Y, Terao N, et al. p53 mutation arising in arg72 allele in the tumorigenesis and development of carcinoma of the urinary tact. Clin Cancer Res 2002; 8:1192-1195.
11. Papadakis ED, Soulitzis N, Spandidos DA. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer 2002; 21:1013-1018.
12. Kawaguchi H, Ohno S, Araki K, Miyazaki M, Saeki H, Watanabe M, et al. p53 polymorphism in human papillomavirus-associated esophageal cancer. Cancer Res 2000; 60:2753-2755.
13. Bonafé M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, et al. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 2003; 9:4860-4864.
14. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003; 3:387-402.
15. Rutqvist L-E, Cedermark B, Glas U, Johansson H, Rotstein S, Skoog L, et al. Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials. Int J Radiat Oncol Biol Phys 1989; 16:629-639.
16. Askmalm MS, Carstensten J, Nordenskjöld B, Olsson B, Rutqvist LE, Skoog L, et al. Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients. Acta Oncol 2004; 43:235-244.
17. Langerød A, Bukholm IRK, Bregård A, Lønning PE, Andersen TI, Rognum TO, et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 2002; 11:1684-1688.
18. Beckman G, Birgander R, Själander A, Saha N, Holmberg PÅ, Kivelä A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered 1994; 44:266-270.
19. Jones JS, Chi X, Gu X, Lynch PM, Amos CI, Frazier ML. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in Caucasian population. Clin Cancer Res 2004; 10:5845-5849.
20. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev 2002; 2:101-112.
21. Keen JC, Dixon JM, Miller EP, Cameron DA, Chetty U, Hanby A, et al. The expression of Ki-S1 and Bcl-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. Breast Cancer Res Treat 1997; 44:123-133.
22. Cameron DA, Ritchie AA, Langdon S, Anderson TJ, Miller WR. Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression. Breast Cancer Res Treat 1997; 45:99-107.
23. Thiantanawat A, Long BJ, Brodie AM. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res 2003; 63:8037-8050.
24. Mandlekar S, Kong ANT. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001; 6:469-477.